Skip to main content

Table 6 Nationwide annual cost of managing HAE episodes with icatibant (Euros)

From: Social costs of icatibant self-administration vs. health professional-administration in the treatment of hereditary angioedema in Spain

 

Most favourable scenario

Least favourable scenario

Variable

Strategy 1 (€)

Strategy 2 (€)

Savings (€)

Savings (%)

Strategy 1 (€)

Strategy 2 (€)

Savings (€)

Savings (%)

Direct costs

21,819,956

20,194,340

1,625,616

7.45

1,121,218

1,048,929

72,289

6.45

Medical

21,655,858

20,177,846

1,478,012

6.82

1,116,431

1,047,707

68,723

6.16

   Icatibant

20,025,875

20,025,875

0

0.00

1,024,811

1,024,811

0

0.00

   Visits*

1,559,016

150,900

1,408,116

90.32

90,390

22,808

67,581

74.77

   Admissions

66,974

938

66,037

98.60

929

58

871

93.78

   Tracheotomy

3,992

133

3,859

96.67

301

30

271

90.00

Non-medical

164,099

16,494

147,604

89.95

4,787

1,222

3,565

74.47

   Transportation

164,099

16,494

147,604

89.95

4,787

1,222

3,565

74.47

Indirect costs

873,371

183,627

689,743

78.97

28,643

10,613

18,030

62.95

   Caretaker

280,398

88,246

192,152

68.53

9,800

3,964

5,837

59.55

   Labor loss

258,830

84,243

174,587

67.45

10,445

4,130

6,315

60.46

   Death

334,142

11,138

323,004

96.67

8,398

2,519

5,878

70.00

Social costs

22,693,327

20,377,967

2,315,360

10.20

1,149,861

1,059,542

90,319

7.85

  1. Strategy 1= Health professional-administration only; Strategy 2= Self-administration also available.
  2. *Includes visits to hospital emergency rooms, primary care centres emergency rooms, and to HAE specialist offices.
  3. Sensitivity analysis.